SCHEMBL4483465

SCHEMBL4483465

O=C(O)C[C@H](O)c1ccc(O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.54
HIF1A Q16665 2/20 0.54
HTR3A P46098 1/20 0.54
TSHR P16473 1/20 0.54
NFKB1 P19838 1/20 0.54
TDP1 Q9NUW8 3/20 0.52
KDM4E B2RXH2 2/20 0.52
ALOX15 P16050 2/20 0.52
APEX1 P27695 1/20 0.52
CYP2C9 P11712 2/20 0.48
ALDH1A1 P00352 1/20 0.48
HTR1A P08908 1/20 0.48
THPO P40225 1/20 0.48
BLM P54132 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NMUR2 Q9GZQ4 1/20 0.48
CA2 P00918 1/20 0.45
CAMK2A Q9UQM7 1/20 0.45
SRC P12931 1/20 0.42
ESR1 P03372 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5864212 1.00 TAAR1 (0.54) TAAR1HIF1AHTR3ATSHRNFKB1
SCHEMBL4483463 1.00 TAAR1 (0.54) TAAR1HIF1AHTR3ATSHRNFKB1
Benzylamine SCHEMBL4505956 0.85 TAAR1 (0.49) TAAR1HIF1AHTR3ATSHRNFKB1
Butyl Alcohol SCHEMBL4496290 0.83 TAAR1 (0.40) TAAR1HIF1AHTR3ATSHRNFKB1
SCHEMBL904490 0.82 GABBR2 (0.55) TAAR1KDM4ESMN1; SMN2SRCLMNA
SCHEMBL186610 0.82 GABBR2 (0.55) TAAR1KDM4ESMN1; SMN2SRCLMNA
SCHEMBL2285716 0.82 CA2 (0.48) TAAR1HIF1AHTR3ATSHRNFKB1
SCHEMBL904476 0.82 GABBR2 (0.55) TAAR1KDM4ESMN1; SMN2SRCLMNA
SCHEMBL1503961 0.81 GABBR2 (0.59) TSHRNFKB1CYP2C9BLMLMNA
SCHEMBL7415181 0.81 FFAR1 (0.50) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7498431-B2 Process for the preparation of chiral azetidinones FRAMROZE BOMI PATEL 2009-03-03 US claimed
US-20070129540-A1 Process for the preparation of chiral azetidinones OPUS ORGANICS PVT LIMITED (IN) 2007-06-07 US claimed
US-7002008-B2 Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one FRAMROZE BOMI PATEL 2006-02-21 US claimed
US-7498431-B2 Process for the preparation of chiral azetidinones FRAMROZE BOMI PATEL 2009-03-03 US disclosed
US-7498431-B2 Process for the preparation of chiral azetidinones FRAMROZE BOMI PATEL 2009-03-03 US disclosed
US-7498431-B2 Process for the preparation of chiral azetidinones FRAMROZE BOMI PATEL 2009-03-03 US disclosed
US-20070129540-A1 Process for the preparation of chiral azetidinones OPUS ORGANICS PVT LIMITED (IN) 2007-06-07 US disclosed
US-20070129540-A1 Process for the preparation of chiral azetidinones OPUS ORGANICS PVT LIMITED (IN) 2007-06-07 US disclosed
US-20070129540-A1 Process for the preparation of chiral azetidinones OPUS ORGANICS PVT LIMITED (IN) 2007-06-07 US disclosed
US-20040254369-A1 Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one FRAMROZE BOMI PATEL (IN) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129540-A1 Process for the preparation of chiral azetidinones CYP1B1, ALDH7A1, CYP3A5 TAAR1 4377/4885HIF1A 4076/4885HTR3A 1614/4885
US-20040254369-A1 Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one HPD, PAH, CYP4B1 TAAR1 3865/4885HIF1A 974/4885HTR3A 591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.